Skip to main content
    T

    Telomir Pharmaceuticals, Inc. Common Stock (TELO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.48
    -0.01 (-1.96%)

    Market Cap: $36.15M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Telomir Pharmaceuticals, Inc. Common Stock (TELO) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Telomir Pharmaceuticals, Inc. Common Stock are Plus Therapeutics (PSTV), Gain Therapeutics (GANX) and Mink Therapeutics (INKT). By market cap, Telomir Pharmaceuticals, Inc. Common Stock ranks 5th of the 13 companies on this page; Actinium Pharmaceuticals (ATNM) is the largest at $51.56M.

    Peer Comparison

    TELO's revenue growth of 0.0% is in line with the peer median. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Telomir Pharmaceuticals, Inc. Common Stock (TELO)$36.15MN/AN/A0.0%N/A0.0%0.00%
    Plus Therapeutics Inc (PSTV)$26.64MN/A2.0x-230.2%-827.8%-2.9%0.00%
    Gain Therapeutics Inc (GANX)$46.31MN/AN/A0.0%-170.5%-100.0%0.00%
    Mink Therapeutics Inc (INKT)$47.95MN/A236.3x0.0%N/A0.0%0.00%
    Actinium Pharmaceuticals Inc (ATNM)$51.56M4.1x1.3x32.2%N/A-100.0%0.00%
    Transcode Therapeutics Inc (RNAZ)$22.35MN/AN/A0.0%-412.7%0.0%0.00%
    Estrella Immunopharma Inc. (ESLA)$22.36MN/AN/A0.0%N/A0.0%0.00%
    Pelthos Therapeutics Inc. (PTHS)$29.24MN/A0.5x-199.5%-95.4%0.0%0.00%
    NextCure Inc (NXTC)$29.31MN/AN/A0.0%N/A-100.0%0.00%
    INmune Bio Inc (INMB)$32.51MN/AN/A0.0%N/A257.1%0.00%
    Grace Therapeutics, Inc. (GRCE)$38.08MN/AN/A0.0%N/A0.0%0.00%
    OS Therapies Incorporated (OSTX)$34.87MN/AN/A0.0%218.0%0.0%0.00%
    Lite Strategy, Inc. (LITS)$25.30MN/AN/A0.0%N/A0.0%0.00%
    Peer median$30.91M4.1x1.7x0.0%-170.5%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Telomir Pharmaceuticals, Inc. Common Stock, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Plus Therapeutics Inc (PSTV)
    Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacturing...
    PSTV competitors
    Gain Therapeutics Inc (GANX)
    Gain Therapeutics, Inc., a developing biotechnology company, is dedicated to developing a variety of therapies to treat diseases caused by protein misfolding.
    GANX competitors
    Mink Therapeutics Inc (INKT)
    MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of allogeneic...
    INKT competitors
    Actinium Pharmaceuticals Inc (ATNM)
    Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplantation...
    ATNM competitors
    Transcode Therapeutics Inc (RNAZ)
    TransCode Therapeutics, Inc., a biopharmaceutical company, is dedicated to the development and commercialization of drugs for the treatment of metastatic...
    RNAZ competitors
    Estrella Immunopharma Inc. (ESLA)
    Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States.
    ESLA competitors
    Pelthos Therapeutics Inc. (PTHS)
    Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens.
    PTHS competitors
    NextCure Inc (NXTC)
    NextCure, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of novel immunomedicines to treat cancer and other...
    NXTC competitors
    INmune Bio Inc (INMB)
    INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on reprogramming the patient's innate immune system to treat cancer, Alzheimer's disease...
    INMB competitors
    Grace Therapeutics, Inc. (GRCE)
    Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada.
    GRCE competitors
    OS Therapies Incorporated (OSTX)
    OS Therapies Incorporated is a pioneering biopharmaceutical company committed to developing innovative treatments for unmet medical needs...
    OSTX competitors
    Lite Strategy, Inc. (LITS)
    Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer.
    LITS competitors

    Frequently Asked Questions About TELO

    Who are Telomir Pharmaceuticals, Inc. Common Stock's main competitors?

    The companies most similar to Telomir Pharmaceuticals, Inc. Common Stock include Plus Therapeutics (PSTV), Gain Therapeutics (GANX), Mink Therapeutics (INKT), Actinium Pharmaceuticals (ATNM) and Transcode Therapeutics (RNAZ), listed from the closest match.

    Who is Telomir Pharmaceuticals, Inc. Common Stock's biggest competitor?

    Actinium Pharmaceuticals (ATNM) is the largest of the similar companies at $51.56M; Plus Therapeutics (PSTV) is the closest match by business profile, size, sector and industry.

    How does TELO stock compare with its competitors?

    TELO's net margin is 0.0% against a peer median of 0.0%.

    Which of Telomir Pharmaceuticals, Inc. Common Stock's competitors pays a higher dividend?

    Telomir Pharmaceuticals, Inc. Common Stock pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Telomir Pharmaceuticals, Inc. Common Stock bigger than its competitors?

    No. Telomir Pharmaceuticals, Inc. Common Stock is 5th by market cap among the 13 companies on this page; the largest is Actinium Pharmaceuticals (ATNM) at $51.56M.